+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Efavirenz"

HIV Drugs Market Report 2025 - Product Thumbnail Image

HIV Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Pregnancy and Anti-Infective Agents - Product Thumbnail Image

Pregnancy and Anti-Infective Agents

  • Book
  • November 2020
From
Antiviral Therapeutics - Technologies, Markets & Companies - Product Thumbnail Image

Antiviral Therapeutics - Technologies, Markets & Companies

  • Report
  • November 2021
  • 620 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Efavirenz is an antiretroviral drug used to treat HIV infection and AIDS. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the action of the enzyme reverse transcriptase, which is needed for HIV to replicate. Efavirenz is usually prescribed in combination with other antiretroviral drugs to reduce the amount of HIV in the body and prevent the development of drug resistance. It is also used to reduce the risk of HIV transmission from mother to child during pregnancy. Efavirenz is a widely used antiretroviral drug and is available in both generic and branded formulations. It is approved for use in adults and children over the age of three months. Common side effects of efavirenz include dizziness, insomnia, headache, and rash. Some companies in the efavirenz market include Merck, Bristol-Myers Squibb, Cipla, Mylan, and Teva Pharmaceuticals. Show Less Read more